Sector: Healthcare
findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for CTLT, sign up here.
Income Statement
Revenue
$4.1bn
Gross Profit
$735.0m
Earning before Tax
$-1.4bn
Net Income
$-1.3bn
Net Income Common Shareholders
$-1.3bn
EPS
-7.19
Balance Sheet
Cash
$229.0m
Debt
$5.0bn
Assets
$10.0bn
Liabilities
$6.3bn
Equity
$3.7bn
Enterprise Value
$12.9bn
Cash Flow Statement
Net Cash from Operations
$174.0m
Net Cash from Investing
$-0.4bn
Net Cash from Financing
$8.0m
Net Cash Flow
$-0.2bn
Free Cash Flow
$-0.3bn
Free Cash Flow per Share
$-1.45
Metrics
Price to Equity
-6.23
Price to Equity (Damodaran)
-6.25
Price to Book
2.20
Net Margin
-0.32
Return on Equity
-0.31
Return on Sales
-0.29
Get immediate access to 5-years of reference grade data for CTLT for free.
Sign upCatalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.
Company Info
Industry
Drug Manufacturers - Specialty & Generic
Employees
18,000
Address
14 Schoolhouse Road
Somerset, NJ 08873
United States
Phone
732 537 6200
Website
Last Updated
2024-02-08
Available Data
Standardized Financial Statements
EOD Price History
Corporate Actions
Institutional Holdings
Insider Transactions
Copyright © findl 2024. All rights reserved.